Meta-Analysis of Novel Glucose-Lowering Agents in Patients With Type 2 Diabetes Mellitus Without Pre-existing Heart Failure

[...]discrepancies in trial and patient characteristics could lead to possible clinical heterogeneity. [...]trials included in this meta-analysis often consist of patients with long-term T2DM, but patients in our study were followed up to a median of only 2.4 years. [...]SGLT2i were most effective i...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2022-07, Vol.174, p.184-188
Main Authors: Ahmed, Aymen, Shahid, Izza, Siddiqi, Ahmed Kamal, Ellahi, Aayat, Shurjeel, Qazi, Rashid, Ahmed Mustafa, Maniya, Talha
Format: Article
Language:English
Subjects:
Clinical trials
Congestive heart failure
Diabetes
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Glucose
Heart failure
Heterogeneity
Meta-analysis
Patients
Population
Prevention
Stroke
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[...]discrepancies in trial and patient characteristics could lead to possible clinical heterogeneity. [...]trials included in this meta-analysis often consist of patients with long-term T2DM, but patients in our study were followed up to a median of only 2.4 years. [...]SGLT2i were most effective in reducing the incidence of HHF/CV death and HHF, whereas GLP-1 agonists reduced HHF/CV death but not HHF.
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2022.04.001